Role of the second-trimester 'genetic sonogram' for Down syndrome screen in the era of first-trimester screening and noninvasive prenatal testing

Prenatal Diagnosis

Volumn 34, Issue 6, 2014, Pages 511-517

  Odibo, Anthony O ^a   Ghidini, Alessandro ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; BIOLOGICAL MARKER;

CELL FREE DNA TESTING; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC SONOGRAM; HIGH RISK PREGNANCY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MOLECULAR DIAGNOSIS; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21; BLOOD; FEMALE; FETUS ECHOGRAPHY; PREGNANCY; PROCEDURES;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; GENETIC TESTING; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; ULTRASONOGRAPHY, PRENATAL;

EID: 84901696021     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4329     Document Type: Review

References (58)

1. Benacerraf BR, Frigoletto FD Jr, Laboda LA. Sonographic diagnosis of Down syndrome in the second trimester. Am J Obstet Gynecol 1985;153:49-52.
2. Bromley B, Lieberman E, Shipp TD, et al. Fetal nose bone length: a marker for Down syndrome in the second trimester. J Ultrasound Med 2002;21:1387-94.
3. Wax JR, Guilbert J, Mather J, et al. Efficacy of community-based second trimester genetic ultrasonography in detecting the chromosomally abnormal fetus. J Ultrasound Med 2000;19:689-94.
4. Aagaard-Tillery KM, Malone FD, Nyberg DA, et al. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009;114(6):1189-96.
5. Agathokleous M, Chaveeva P, Poon LC, et al. Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013;41(3):247-61.
6. Vintzileos AM, Campbell WA, Rodis JF, et al. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet Gynecol 1996;87:948-52.
7. Bahado-Singh RO, Mendilcioglu I, Rowther M, et al. Early genetic sonogram for Down syndrome detection. Am J Obstet Gynecol 2002;187:1235-1238.
8. Odibo AO, Sehdev HM, Gerkowicz S, et al. Comparison of the efficiency of second-trimester nasal bone hypoplasia and increased nuchal fold in Down syndrome screening. Am J Obstet Gynecol 2008;199:281.e1-5.
9. Zalel Y, Achiron R, Yagel S, Kivilevitch Z. Fetal aberrant right subclavian artery in normal and Down syndrome fetuses. Ultrasound Obstet Gynecol 2008;31:25-29.
10. Vos FI, De Jong-Pleij EA, Ribbert LS, et al. Three-dimensional ultrasound imaging and measurement of nasal bone length, prenasal thickness and frontomaxillary facial angle in normal second- and third-trimester fetuses. Ultrasound Obstet Gynecol 2012;39(6):636-41.
11. Borrell A, Costa D, Martinez JM, et al. Early midtrimester fetal nuchal thickness: effectiveness as a marker of Down syndrome. Am J Obstet Gynecol 1996;175(1):45.
12. Gray DL, Crane JP. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome. Am J Obstet Gynecol 1994;171:1282-6.
13. Weisz B, Pandya PP, David AL, et al. Ultrasound findings after screening for Down syndrome using the integrated test. Obstet Gynecol 2007;109: 1046-1052.
14. Carbone JF, Tuuli MG, Dicke JM, et al. Revisiting the risk for aneuploidy in fetuses with isolated pyelectasis. Prenat Diagn 2011;31:566-570.
15. American College of Obstetrics and Gynecology Practice Bulletin #77. Screening for fetal chromosome abnormalities. Obstet Gynecol 2007;109(1):217-227.
16. Royal College of Obstetricians and Gynaecologists. Antenatal screening for Down syndrome. 2003. http://www.rcog.org.uk/womens-health/clinical-guidance/ultrasound-screening#app2
17. Schluter PJ, Pritchard G. Mid trimester sonographic findings for the prediction of Down syndrome in a sonographically screened population. Am J Obstet Gynecol 2005;192(1):10-6.
18. Vergani P, Ghidini A, Weiner S, et al. Risk assessment for Down syndrome with genetic sonogram in women at risk. Prenat Diagn 2008;28(12):1144-8.
19. Odibo AO, Sehdev HM, Stamilio DM, et al. Defining nasal bone hypoplasia in second-trimester Down syndrome screening: does the use of multiples of the median improve screening efficacy? Am J Obstet Gynecol 2007;197:361.e1-4.
20. Locatelli A, Piccoli MG, Vergani P, et al. Critical reappraisal of the use of nuchal fold thickness in the prediction of Down syndrome. Am J Obstet Gynecol 2000;182:192-7.
21. Tsai LJ, Ho M, Pressman EK, et al. Ultrasound screening for fetal aneuploidy using soft markers in the overweight and obese gravida. Prenat Diagn 2010;30:821-6.
22. Benacerraf BR, Neyberg D, Bromley B, et al. Sonographic scoring index for prenatal detection of chromosomal abnormalities. J Ultrasound Med 1992;11:449-458.
23. Smith-Bindman R, Hosmer W, Feldstein VA, et al. 2001. Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis. JAMA 285:1044-1055.
24. Nyberg DA, Luthy DA, Resta RG, et al. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998;12(1):8-14
25. Nyberg DA, Souter VL. Use of genetic sonography for adjusting the risk for fetal Down syndrome. Semin Perinatol 2003;27:130-144.
26. Moreno-Cid M, Tenias JM, Rubio-Lorente A, et al. Systematic review of the clinical prediction rules for the calculation of the risk of Down syndrome based on ultrasound findings in the second trimester of pregnancy. Prenat Diagn 2014, doi:10.1002/pd.4304.
27. Zhong Y, Longman R, Bradshaw R, et al. The genetic sonogram: comparing the use of likelihood ratios versus logistic regression coefficients for Down syndrome screening. J Ultrasound Med 2011;30:463-9.
28. Nicolaides KH, Brizot ML, Snijders RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994;101(9):782-6.
29. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-2011.
30. Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome [published erratum appears in J Med Screen 1998;5(2):110 and 1998;5(3):166]. J Med Screen 1998;4:181-246.
31. Krantz DA, Hallahan TW, Macri VJ, et al. Genetic sonography after first-trimester Down syndrome screening. Ultrasound Obstet Gynecol 2007;29(6):666-70.
32. Shamshirsaz AA, Ravangard SF, Turner G, et al. Efficacy of the genetic sonogram in a stepwise sequential protocol for Down syndrome screening. J Ultrasound Med 2013;32(9):1607-13.
33. Sood M, Rochelson B, Krantz D, et al. Are second-trimester minor sonographic markers for Down syndrome useful in patients who have undergone first trimester combined screening? Am J Obstet Gynecol 2010;203:408.e1-4.
34. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-487.
35. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A 2008;105:16266-16271.
36. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105:20458-20463.
37. Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:1042-1049.
38. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3-9.
39. Ghanta S, Mitchell ME, Ames M, et al. Non-invasive prenatal detection of trisomy 21 using tandem single nucleotide polymorphisms. PLoS One 2010;5:e13184.
40. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32:1233-1241.
41. Tong YK, Jin S, Chiu RW, et al. Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. Clin Chem 2010;56:90-98.
42. Fan HC, Blumenfeld YJ, El-Sayed Y et al. Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy. Am J Obstet Gynecol 2009;200:543.e1-7.
43. Go AT, Visser A, van Dijk M, et al. A novel method to identify syncytiotrophoblast-derived RNA products representative of trisomy 21 placental RNA in maternal plasma. Methods Mol Biol 2008;444:291-302.
44. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119;890-901.
45. Chiu RW, Akolekar R, Zheng YW et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011 11;342:c7401.
46. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207:374.e1-6.
47. Norton ME, Brar H, Weiss J, et al. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207(2):137.e1-8.
48. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-920.
49. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 2013;42:15-33.
50. Dan S, Wang W, Ren J, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11, 105 pregnancies with mixed risk factors. Prenat Diagn 2012;32:1225-1232.
51. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013;42:34-40.
52. American College of Obstetricians and Gynecologists. Noninvasive prenatal testing for fetal aneuploidy. Committee opinion no. 545. Obstet Gynecol 2012;120:1532-1534.
53. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33(7):622-9.
54. Langlois S, Brock J-A. Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can 2013;35:177-181.
55. Mennuti MT, Cherry AM, Morrissette JJ, et al. Is it time to sound an alarm about false-positive cell-free DNA testing for fetal aneuploidy? Am J Obstet Gynecol 2013;209:415-9.
56. Canick JA, Palomaki GE, Kloza EM, Lambert-Messserlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667-74.
57. Aagaard-Tillery KM, Flint Porter T, Malone FD, et al. Influence of maternal BMI on genetic sonography in the FASTER trial. Prenat Diagn 2010;30:14-22.
58. Fehmi Yazoǧlu H, Sevket O, Akn H, et al. Aberrant right subclavian artery in Down syndrome fetuses. Prenat Diagn 2013;33:209-13.